A MOST INTRIGUING EXAMPLE of gain-of-function mutations in G protein ␣-subunits causing human disease is the case of McCune-Albright syndrome (MAS) (11) . MAS is a sporadic disease typified by precocious puberty, monoostotic or polyostotic fibrous dysplasia, café au lait pigmentation, and several endocrinopathies (23) . Hyperthyroidism, Cushing syndrome, hyperparathyroidism, acromegaly, and hepatomegaly are frequently observed in patients with this syndrome. The hyperactivity of the endocrine tissues appears to result from activating mutations (e.g., Arg 201 ) in G␣ s that generate gain of function (23) . The expression of activated G␣ s is not uniform in MAS but rather is a complex pattern reflecting the occurrence of a mutation in the multicell developing embryo. This feature of the disease generates a mosaic of expression that reflects the fate map of the cell in which the mutation arises. Patients with MAS are true chimera, the severity of the disease manifested largely by the spectrum of organs and tissues in which activated G␣ s occurs. Recent studies suggest that a severe form of the syndrome may be the cause of early death in childhood, especially when the activated G protein is expressed in tissues such as the liver, heart, and gastrointestinal tract, nonclassic targets of MAS (18, 19) .
The impact of gain-of-function mutations of G␣ s on signaling has been examined in a variety of cell types in culture, including neuroblastoma ϫ glioma hybrid NG108-15 cells (14) , mouse NIH 3T3-L1 (4), Swiss 3T3 cells (27) , rat pituitary GH3 cells (6) , and FRTL-5 rat thyroid cells (15) . G␣ s is known to regulate adenylyl cyclase activity, Ca 2ϩ channels, and apoptosis (17, 24) . Study of the stoichiometry of G␣ s protein-coupled receptors, G␣ s , and adenylyl cyclase suggests that G␣ s is in molar excess of receptor and effector (16) . Spatial compartmentation and oligomerization of elements in the receptor Ͼ G␣ s Ͼ effector cascade may well negate the simple stoichiometry (16) , because loss of ϳ50% of the G␣ s complement in Albright hereditary osteodystrophy leads to reduced signaling to adenylyl cyclase in humans (10, 21) . These data suggest that probing the functions of G␣ s in vivo may best be approached by targeted expression of a constitutively activated form of G␣ s rather than wild-type G␣ s . Expression of wildtype G␣ s may contribute to endogenous levels of this G protein that may already be in excess of G proteincoupled receptors, whereas expression of Q227L G␣ s leads to a situation of chronic activation of G␣ s -regulated effectors. Overexpression of wild-type G␣ s in hearts of transgenic mice has been accomplished with the rat ␣-myosin heavy chain promoter (2) . mRNA levels for G␣ s in the transgenic mice increased nearly 40-fold and G␣ s expression in the heart increased less than threefold, whereas there was little evidence by histopathological evaluation of the myocardium for lesions in the young adult (4-7 mo old) animals (2) . These transgenic mice do develop increased cardiac contractility in response to ␤-adrenergic stimulation and with aging cardiomyopathy (3) .
Targeted expression of constitutively activated mutant forms of G␣ s in transgenic mice may provide a useful model for study of G␣ s function in specific tissues. The physiological mechanism(s) by which changes in G protein subunit expression are regulated and the extent to which cells adapt to changes in signaling in response to mutations in G protein ␣-subunits remain to be established and will be essential to our understanding of G protein signaling in human diseases. Creation of mice with tissue-specific expression of an activated G␣ s may provide insights into the adaptive mechanisms that arise to ameliorate the increase in cAMP levels.
EXPERIMENTAL PROCEDURES
Construction of pPEPCK-Q227L G␣s plasmid. The cDNA encoding the Q227L mutant of G␣s was engineered into convenient restriction sites of the pPEPCKQ205L G␣i2 vector as previously reported (1) . The coding sequence of a constitutively activated G␣ s (Q227L) and 3Ј-untranslated region (212 bp) was employed to replace the phosphoenolpyruvate carboxykinase (PEPCK) coding sequence, remaining under the control of PEPCK promoter.
Transfection and screening of FTO-2B cells. The calcium phosphate precipitation method was used in transfection of FTO-2B cells, which are normally grown in DMEM containing 5% FBS at 37°C under humidified 95% air-5% CO 2 (12) . The procedures used in the transfection, selection, and induction of the stably transfected FTO-2B clones with 8-(4-chlorophenylthio)adenosine 3Ј,5Ј-cyclic monophosphate (CPT-cAMP) were described previously (1) .
Creation of transgenic mice with conditional, tissue-specific expression of Q227L G␣ s. The Q227L G␣s and PEPCK promoter (3.7 kb) were excised by XhoI and NotI from the pPEPCKQ227L G␣ s construct and isolated by low-melting agarose gel electrophoresis. The constructs were injected into preimplantation embryos, which were transplanted into pseudo-pregnant mice (C57Black6) in the University Transgenic Mouse Facility at the State University of New York at Stony Brook. Mouse tail DNAs were isolated with a DNeasy Tissue Kit according to the manufacturer's protocol and used for PCR amplification. The primers used were GACATCATC-CAGCGCATGCATC (PT1) and CATCGGGATTACATCTG-GCTGA (PT2), which on amplification yield a 574-bp fragment specific for the PEPCK-Q227L G␣ s construct. The amplification products were applied to electrophoresis on 1.5% agarose gels and made visible in ethidium bromide under ultraviolet irradiation. Transgenic mice were mated with wild-type C57Black6 mice purchased from Taconic (Germantown, NY) for five generations. Glucose tolerance tests and insulin sensitivity tests were performed as previously described (13) . Wild-type control mice were littermates of the transgenic animals. The target age for analysis was 4 wk for identification of the transgenic mice and 4 mo for all other analyses. Only in the case where the intent was to sample mice at older ages for a phenotype were either 7-or 18-mo-old animals used.
Reverse transcription-polymerase chain reaction. Total mRNA was isolated and purified from cultured cells or tissues with RNA STAT-60 according to the manufacturer's instruction. Reverse transcription (RT) was conducted with 1 g of total RNA in a final volume of 20 l at 42°C for 1 h with the Promega RT system. Aliquots (4 l) of RT product were applied to each polymerase chain reaction (PCR) and 30 cycles of amplification. For screening of transfected FTO-2B cells, primers PT1 and PT2 were used in the PCR amplifications. To probe tissue-specific expression of both the endogenous G␣ s mRNA and the mRNA of the transgene, additional primers were prepared. The 5Ј and 3Ј primers specific for endogenous G␣ s and Q227L G␣s were 5Ј-TGG GTG CTG GAG AG TCTG G-3Ј (S1m) and 5Ј-AGG AAG TAC TGG GCA CAG T5Ј (S2m), respectively. A unique 5Ј primer, 5Ј-AGG GCT AGA CTC GAC ATG GGC T3Ј (S3m), specific only for the PEPCK-Q227L G␣ s transgene, was used to differentiate mRNAs of the mutant and wild-type forms. The PCR using primers S1m and S2m produces a 400-bp product from endogenous G␣ s and Q227L G␣s, whereas the PCR using primers S3m and S2m produces a 551-bp product from PEPCK-Q227L G␣ s transgene only.
Isolation of adipocytes. Fat tissues were collected, minced, and digested with collagenase type 4 (1 mg/ml) in KrebsRinger Buffer [KRB; in mM: 120 NaCl, 4.8 KCl, 2.6 CaCl 2, 1.2 MgSO 4, 25 NaHCO3, 1 sodium phosphate buffer (pH 7.4), 2.5 D-glucose, and 5 HEPES] containing 3% bovine serum albumin (BSA) at 37°C on a shaker (100-150 rpm) for 30 min. The adipocytes were washed three times with KRB and transferred into KRB containing 3% BSA, 0.1 mM Ro-20-1724 (unless otherwise noted), and adenosine deaminase for cAMP production assays.
Adipocyte cAMP production assays. Assays were conducted in 1.5-ml test tubes in triplicate sets. The ␤-adrenergic agonist isoproterenol and/or the diterpene forskolin were prepared in 50 l of ice-cold KRB buffer containing Ro-20-1724 and adenosine deaminase; this aliquot was added to the incubation tubes first. The KRB buffer minus cells served as basal control. The reaction was started by addition of adipocytes (10,000-50,000/tube) and incubated at 37°C for 15 min on a shaker (300 rpm). To stop the reaction, the tubes were returned to an ice bath and 300 l of prechilled (Ϫ20°C) ethanol was added to each well. The assay of the cAMP was as described elsewhere (20) .
Protein kinase A assays. The assay is based on the phosphorylation of a synthetic peptide substract (kemptide: LeuArg-Arg-Ala-Ser-Leu-Gly) by cAMP-dependent protein kinase (protein kinase A; PKA) in the presence of [␥-
32 P]ATP. The enzyme activity of PKA was determined with a PKA assay kit in triplicate in a final volume of 40 l according to the manufacturer's protocol (20) . The reaction contained 50 mM Tris (pH 7.5), 100 mM MgCl2, and 100 M ATP supplemented with [␥-32 P]ATP, 0.25 mg/ml BSA, and 50 M PKA substrate peptide kemptide. "Basal" PKA activities were determined in the absence of the PKA activator, cAMP, and defined as the PKA activity sensitive to inhibition by PKA inhibitor (PKI). PKI, a 17-amino acid peptide derived from the PKI sequence (1 M final), was included to determine PKA-specific protein kinase activity. "Total" PKA activities were determined in the presence of 10 M cAMP.
Briefly, fat tissues taken from mice were homogenized with a glass homogenizer fitted with a glass pestle and extraction buffer (in mM: 5 EDTA and 50 Tris, pH 7.5). The whole homogenate was cleared of cell debris by 2,000 g centrifugation for 15 min at 4°C, and the supernatant was recovered for PKA activity assay. The reaction was carried out at 30°C for 5 min. Aliquots (20 l) were spotted onto phosphocellulose paper disks. The disks were washed three times with phosphoric acid (1% vol/vol) for 5 min and then rinsed once with acetone. The radioactivity of 32 P contained in the disk papers was then counted by liquid scintillation counter. The PKA activity was defined as picomoles of [ 32 P]phosphate transferred to kemptide substrate per minute per milligram of protein.
Phosphodiesterase activity assays. Fat tissues were collected and homogenized with a glass homogenizer in TMK buffer (in mM: 40 Tris, 5 MgCl2, and 30 KCl, pH 8.0) containing proteinase inhibitors [5 g/ml aprotinin, 5 g/ml leupeptin, and 200 M phenylmethylsulfonyl fluoride (PMSF)] as described. After 2,000 g centrifugation, supernatants were collected for total phosphodiesterase (PDE) activity measurement. Briefly, PDE activity was determined in 1.5-ml microtubes (duplicate sets) with a final volume of 100 l of TMK buffer containing cold cAMP (5.0 M) and 0.05 Ci of [
3 H]cAMP as substrate. The reaction was initiated by addition of 50 g of proteins and incubated in a shaker (300 rpm) at 37°C for 10 min. At the end of the 10-min incubation, tubes were placed in a boiling water bath for 3 min. Snake venom (100 l of 1 mg/ml) was then added to convert 5Ј-AMP to adenosine by a 10-min incubation at 37°C in the shaker. Adenosine was then separated by addition of 1 ml of AG1-X8 resin (chloride form) to each tube. The tubes were then centrifuged for 15 min at 600 rpm. An aliquot of 500 l of supernatant was counted for radioactivity in 3 ml of Ecoscint H. TMK buffer served as blanks. Ro-20-1724 (100 M) was added to inhibit PDE4 activity.
Immunoblot analysis. FTO-2B cells were collected in PBS-EDTA buffer and suspended in ice-cold HME buffer (in mM: 20 HEPES pH 7.4, 2 MgCl 2, and 1 EDTA) containing proteinase inhibitors (5 g/ml aprotinin, 5 g/ml leupeptin, and 200 M PMSF). The suspension was sonicated for 10 s at a setting of 3 with a 550 Sonic Dismembrator from Fisher Scientific (Pittsburgh, PA). Animal tissues were collected and homogenized with a glass homogenizer in the presence of ice-cold HME buffer containing proteinase inhibitors. Intact cells and nuclei were then removed by low-speed centrifugation (2,000 g) at 4°C for 5 min, and supernatant was recovered. Membrane proteins were collected by high-speed centrifugation (16,000 g) at 4°C for 30 min. Protein pellets were resuspended in cold HME buffer containing proteinase inhibitors, and concentration was determined by a Lowry assay. For detection of G␣ s and G␣i2 subunits, membrane proteins (30-100 g) were subjected to SDS-polyacrylamide gel electrophoresis (PAGE). For PKA catalytic and regulatory subunits, whole homogenate (supernatant after 2,000 g; 10-100 g protein) was subjected to SDS-PAGE. The separated proteins were transferred to nitrocellulose membranes, and the blots were stained with a rabbit polyclonal antibody specific for G␣s subunit (CM129), mouse monoclonal antibodies for PKA catalytic and regulatory subunits, and then the second antibody peroxidase-labeled goat anti-rabbit or goat antimouse IgG. The immune complexes were visualized with enhanced chemiluminescence (ECL) methods and quantified with a GS-700 Imaging Densitometer (Bio-Rad Laboratories, Hercules, CA).
Materials. The DNeasy Tissue Kit for mouse tail DNA isolation was purchased from Qiagen (Valencia, CA). Reagents for PCR reactions were obtained from Life Technologies (Gaithersburg, MD). All PCR primers were synthesized by Operon Technologies (Alameda, CA). A cAMP-specific PDE inhibitor, Ro-20-1724, was purchased from Calbiochem (San Diego, CA). A stable analog of cAMP, CPT-cAMP, was purchased from Boehringer-Mannheim (Indianapolis, IN). A total RNA/mRNA isolation reagent, RNA STAT-60, was purchased from Tel-Test (Friendswood, TX). Horseradish peroxidase-labeled goat anti-rabbit IgG was purchased from Kirkegaard and Perry Laboratories (Gaithersburg, Maryland). An ECL Western detection kit was purchased from NEN Life Science Products (Boston, MA). [ 3 H]cAMP and [␥-32 P]ATP were purchased from NEN. Collagenase type 4 was purchased from Worthington Biochemical (Lakewood, NY). AG 1-X8 resin was purchased from Bio-Rad Laboratories. Ecoscint H was purchased from National Diagnostics (Atlanta, GA). Snake venom, adenosine, cAMP, inosine, BSA, and all other chemicals were purchased from Sigma (St. Louis, MO). The PKA assay system was purchased from Life Technologies. Mouse monoclonal antibodies for PKA catalytic subunit (PKA cat) regulatory units I␣, II␣, and II␤ were ordered from BD Transduction Laboratories (Lexington, KY).
RESULTS
The expression of the Q227L constitutively activated G␣ s was directed by use of the promoter for the PEPCK gene (Fig. 1A) . The expression vector harboring Q227L G␣ s was first screened for expression in FTO-2B rat hepatoma cells, cells that enable induced expression of the PEPCK gene. FTO-2B clones stably transfected with the pPEPCK-Q227L G␣ s construct should display induction of the Q227L G␣ s in response to the positive regulator of the PEPCK gene, cAMP (Fig. 1B) . Treatment of the clones with CPT-cAMP (25 M) resulted in a robust expression of the transgene, as evidenced by RT-PCR amplification of the mRNA. The promoter was not found to be "leaky," i.e., the transgene mRNA was not detected in these clones in the absence of added CPT-cAMP. Expression of the Q227L G␣ s at the protein level in the FTO-2B clones induced with 25 M CPT-cAMP was demonstrated by using immunoblotting with an antibody specific for G␣ s (Fig. 1C) . Neither the wild-type FTO-2B cells nor the clones stably transfected with the pPEPCK-Q227L G␣ s plasmid but not treated with CPT-cAMP, in contrast, displayed increased expression of immunoreactive G␣ s . Quantification of the blots from several independent clones revealed a 40-50% increase in the total amount of G␣ s (endogenous G␣ s ϩ expressed Q227L G␣ s ), indicative of significant expression of the mutant G␣ s over that of wild-type G␣ s .
The linearized XhoI-NotI fragment (3.7 kb) was injected into preimplantation single-cell embryos to generate transgenic mice. Transgenic mice were identified at 4 wk of age by PCR amplification of tail DNA ( Fig.  2A) . Three founder lines were identified and propagated. The bulk of the studies were performed with mice that were 4 mo of age, unless otherwise noted. RT-PCR amplification was performed with primers common to all forms of G␣ s as well as with primers that would hybridize only with Q227L G␣ s DNA (Fig. 2B) . Expression of the mRNA encoding the Q227L G␣ s was observed in the fat and liver target tissues, but not in kidney, of the transgenic but not the wild-type (nontransgenic littermates) mice. Examination at the level of protein expression in these transgenic mice revealed expression of increased immunoreactive G␣ s in tissues that are targeted by the PEPCK promoter, i.e., fat, liver, and skeletal muscle (Fig. 2C) . The amount of mutant G␣ s expressed in vivo, equivalent to the differences in total immunoreactive G␣ s between the transgenic and the wild-type mice, was similar to that expressed in the stably transfected FTO-2B cells when challenged with cAMP (Fig. 1C) . Tissues of the transgenic mice that are not targeted by the PEPCK promoter used in these studies, such as kidney, spleen, and brain (not shown), displayed no apparent increase in the amount of immunoreactive G␣ s (Fig. 2C) . The nontargeted kidney and spleen tissues expressed the same amount of G␣ s in transgenic mice as in mice of the same age and sex as the transgenic counterparts (Fig. 2C ) or nontransgenic littermates (not shown). We examined the expression of immunoreactive G␣ s in fat tissue of transgenic Q227L G␣ s mice and wild-type mice at 4 and 7 mo of age (Fig. 2D) . The increased expression of immunoreactive G␣ s attributed to the expression of Q227L G␣ s was maintained up to 7 mo of age. The expression of G␣ i2 was also examined, because it has been shown that increased levels of cAMP provoke increased expression of G␣ i2 (5) . Expression of G␣ i2 was found to be increased in fat tissue of the transgenic mice at both 4 and 7 mo of age (Fig. 2D) . The expression of G␣ i2 in the liver, in contrast, was not found to be enhanced in the transgenic mice at 4 mo of age and only slightly increased in liver from 7-mo-old Q227L G␣ s mice compared with wild-type mice (Fig.  2E) .
The breeding and macroscopic phenotype of the Q227L G␣ s mice were found to be unremarkable, with growth curves for both male and female transgenic mice tracking identically with their nontransgenic counterparts (not shown). Necropsy data suggested some mixed inflammatory cell infiltrates in the liver and skeletal muscle but no routine significant lesions. Alterations in the expression of G␣ s , such as observed in Albright hereditary osteodystrophy and in hemizygous/heterozygous G␣ s knockout mice, have been shown to lead to changes in insulin action and glucose metabolism. Increased insulin sensitivity has been reported in such G␣ s knockout mice (25) . We examined the glucose metabolism of the Q227L G␣ s mice. In glucose tolerance tests, the Q227L G␣ s mice demonstrated a markedly suppressed ability to rectify blood glucose levels in response to a bolus administration of glucose (Fig. 3) . The Q227L G␣ s mice required an additional Ͼ2-3 h after bolus administration of glucose to achieve the blood glucose levels of their nontransgenic counterparts. Insulin sensitivity curves derived from studies with fasted Q227L G␣ s vs. control littermates performed over a range of insulin concentrations (0.75-6.0 IU/kg) were not significantly different (not shown).
Biochemical analysis of the impact of Q227L G␣ s expression on transgenic mice was performed with white fat cells isolated from the endometrial fat pads of transgenic and control mice. The levels of intracellular cAMP were found to be increased, but only by 25-30% Fig. 1 . Expression of the pPEPCK Q227L G␣s construct in FTO-2B rat hepatoma cells leads to cAMP-inducible expression of the Q227L G␣s A: schematic of the pPEPCK-Q227L G␣s vector. B: inducible expression of Q227L G␣s in stably transfected FTO-2B cells: analysis by reverse transcription-polymerase chain reaction (RT-PCR) amplification of Q227L G␣s. pPEPCK-Q227L G␣s-transfected FTO-2B cells were treated with the cAMP analog 8-(4-chlorophenylthio)adenosine 3Ј,5Ј-cyclic monophosphate (CPT-cAMP; 25 M) for 72 h, and RT-PCR was performed on total RNA. DNA samples from nontransfected FTO-2B cells served as negative control, and PEPCK-Q227L G␣s plasmid served as positive control. Amplification products were applied to electrophoresis on 1.5% agarose gels and made visible in ethidium bromide under ultraviolet irradiation. N, negative control; P, positive control; MK, 100-bp markers. C: inducible expression of Q227L G␣s in transfected FTO-2B cells. pPEPCK-Q227L G␣s-transfected FTO-2B cells were treated with CPT-cAMP (25 M) for 4 days. Cells were harvested, and membrane proteins (50 g protein/lane) were subjected to electrophoresis on a SDS-PAGE and then immunoblotting (IB). Resolved membrane proteins were incubated with a polyclonal rabbit G␣s antibody (CM129) and a second goat antirabbit IgG coupled with horseradish peroxidase. Bands were visualized with enhanced chemiluminescence (ECL) methods and quantified with imaging densitometry. Transgenic mice expressing Q227L G␣s (Q227L) or their nontransgenic wild-type controls (WT) were used. Data represent means Ϯ SE from 4 experiments. A representative of blots is shown. L, lower-mobility "long form" of G␣s; S, higher-mobility "short form." *P Ͻ 0.05 (paired t-test). Fig. 2 . Expression of the pPEPCK Q227L G␣s construct in transgenic mice leads to inducible, tissue-specific expression of Q227L G␣s and G␣i2. A: mouse tail samples (ϳ1 cm long) were collected at age of ϳ4 wk, and genomic DNAs were isolated and amplified by PCR. The PCR products were applied to electrophoresis on 1.5% agarose. Positive identification of 5 mice harboring the Q227L G␣s transgene is observed (lanes 1-5) . M, 100-bp markers; N, negative control with genomic DNA from C57B6 wild type mouse; P, positive control with pPEPCK-Q227L G␣s plasmid as a template. B: RT-PCR amplification of mRNA encoding total G␣s (endogenous ϩ Q227L G␣s) as well as mRNA of the Q227L G␣s only. Samples from fat, liver, and kidney of 4-mo-old Q227L G␣s transgenic (TG) mice and their WT counterparts were subjected to extraction of RNA. Total RNA was subjected to RT-PCR and amplified with primers that detect total G␣s mRNA and primers unique to Q227L G␣s mRNA. PCR products and detection were as in A. C: expression of Q227LG␣s in tissues targeted and not targeted by the PEPCK gene promoter: analysis by immunoblotting with antibodies to G␣s. Tissues were excised from 4-mo-old mice. Fat tissue (30 g protein/lane), liver (100 g protein/lane), and muscle (100 g protein/lane), all targeted tissues for the PEPCK gene promoter, displayed increased expression of G␣s, representing endogenous G␣s and expressed Q227L G␣s. Immunoblots of tissues, such as kidney (50 g/lane) and spleen (50 g/lane), not targeted for expression by the PEPCK promoter displayed equivalent expression of G␣s in WT and TG mice. Target and nontarget tissues were taken from TG animals and WT littermates. Immune complexes were visualized with ECL methods and quantified with imaging densitometry. Data represent means Ϯ SE from 4 experiments. A representative of blots is shown. *P Ͻ0.05 (paired t-test). D: Expression of G␣s, G␣i2, and G␤2 in fat tissue obtained from Q227L mice and their WT counterparts. Tissues were excised from either the standard 4-mo-old mice or from 7-mo-old mice. Samples from fat were processed and expression of the G protein ␣-subunits was detected as in C. E: expression of G␣i2 in liver tissue obtained from Q227L mice and their WT counterparts. Tissues were excised from the standard 4-mo-old mice or from 7-mo-old mice. Samples from liver were processed and expression of the G protein ␣-subunits was detected as in C. (Fig. 4 ). In view of the level of expression of Q227L G␣ s and its constitutively active nature, we were surprised by the magnitude in the increase in basal cAMP levels of the fat cells from these mice. These relationships between the cAMP responses of the Q227L G␣ s mice vs. their nontransgenic littermates were the same in the absence (not shown) or presence (Fig. 4) of 0.1 mM RO20-1724, an inhibitor of cAMP-specific PDE activity. Furthermore, the cAMP response to stimulation with either a range of ␤-adrenergic agonist (isoproterenol) or the plant diterpene forskolin was not significantly different although it was routinely greater in Q227L G␣ s compared with control mice. These data suggested that some adaptive mechanism(s) must be operating to nullify the output of the expression of the constitutively active Q227L G␣ s in vivo. The increased expression of the antagonistic heterotrimeric G protein G␣ i2 (Fig. 2, D and E) likely plays some role in dampening the signaling of G␣ s to adenylyl cyclase.
There is ample literature to demonstrate that elevating intracellular cAMP levels can provoke increases in PDEs that metabolize the cyclic nucleotide. We compared the bulk cAMP-specific PDE activity of fat cells from control mice with those of mice expressing Q227L G␣ s (Fig. 5) . Total PDE activity increased ϳ15% in the fat cells from the Q227L G␣ s mice. Most of the increase was observed in the PDE activity that was sensitive to inhibition by the PDE inhibitor Ro-20-1724. Although PDE activity was increased in the fat cells expressing Q227L G␣ s , the increase in Ro-20-1724-sensitive PDE was modest and provided only a partial answer.
The expression of a constitutively activated G␣ s would be expected to increase the activation of the cAMP-dependent protein kinase (PKA). Basal and total PKA activities were measured in adipocytes isolated acutely from mice expressing the Q227L G␣ s as well as from wild-type, nontransgenic littermates (Fig.  6A) . Total PKA activities for adipocytes from Q227L G␣ s mice were not significantly different from those of adipocytes from wild-type controls. Remarkably, in contrast to the expected increased PKA activity, we observed a Ͼ50% decline in the amount of basal PKA activity in the Q227L G␣ s mouse adipocytes. These unexpected results were explored by immunoblotting with anti-PKA antibodies to ascertain the relative amounts of the PKA catalytic subunit (PKA cat) in adipocytes from wild-type and Q227L G␣ s mice (Fig.   Fig. 5 . Expression of Q227L G␣s in vivo leads to increased cAMPspecific PDE activity in adipose tissue. Fat pads excised from 4-moold Q227L mice and WT littermates were homogenized with a glass/ glass homogenizer. The supernatant was collected by 2,000 g centrifugation for 10 min at 4°C and immediately assayed for PDE activity in the absence (total) or presence (Ro insensitive) of PDE inhibitor Ro-20-1724 (0.1 mM). Results are mean Ϯ SE values from 4 separate experiments. Nine WT and eight Q227L animals were assayed, each in duplicate. *P Ͻ 0.05 (paired t-test) . Fig. 3 . Expression of the pPEPCK Q227L G␣s construct in transgenic mice leads to impaired glucose tolerance. Q227L mice and control WT littermates of the same age and sex were subjected to a glucose tolerance test. The 4-mo-old mice were administered an intraperitoneal (ip) bolus of glucose, and blood glucose was determined over the next 3 h. Results displayed are mean Ϯ SE values for WT (n ϭ 5) and Q227L (n ϭ 8) mice. Fig. 4 . Expression of Q227L G␣s in adipocytes of TG mice increases basal intracellular cAMP levels. Tissue was excised from 4-mo-old mice. Fat pads of control WT and TG mice were digested with collagenase, and cAMP accumulation was measured in the acutely prepared adipocytes. Isolated adipocytes were incubated in the absence or presence of isoproterenol (Iso; 0.01-10 M) for 15 min at 37°C in buffer containing phosphodiesterase (PDE) inhibitor Ro-20-1724 (100 M). For measurement of basal cAMP, cells were incubated in the absence or presence of Ro-20-1724. The relationships between the TG and WT samples were similar in both cases. Adipocytes were stimulated with forskolin (50 M) as an indirect measure of total adenylyl cyclase activity. Data are means Ϯ SE from at least 4 experiments, each assayed in triplicate. *P Ͻ 0.05 (paired t-test) . 6B). The amount of PKA cat, unlike the total PKA activity (Fig. 6A) , was found to be equivalent for adipocytes from the wild-type and transgenic mice. In parallel, the relative amounts of the regulatory subunits of PKA were determined in adipocytes from both groups. The expression of RI␣, RII␣, and RII␤ subunits was studied via immunoblotting. Blots were prepared from whole cell extracts, subjected to SDS-PAGE, and then stained with subunit-specific antisera. Significant increases in the expression of all of the PKA regulatory subunits were observed (Fig. 6B) . The increases for RI␣ and RII␣ were the greatest, increasing in the adipo-cytes from transgenic mice by 70-80%. The expression of the highly abundant RII␤ subunit was increased by Ͼ20% in fat tissue of the Q227L G␣ s mice. Analysis of the subcellular distribution of PKA catalytic and regulatory subunits revealed quantitative recovery in the postnuclear (2,000 g, 5 min) supernatants rather than in nuclear fractions obtained from whole homogenates of adipose tissue from wild-type as well as Q227L mice (Fig. 6C) . Increased expression of RI␣, RII␣, and RII␤ was also detected in the liver of the Q227L G␣ s mice (data not shown).
In fat and liver, analysis of PKA subunit by SDS-PAGE and immunoblotting did not reveal any gross alterations in the stability of RII␤ subunits, RI␣, and RII␣ (not shown) prepared in the usual cocktail of protease inhibitors (Fig. 6D) . The addition of 0.2 mM benzamidine to this cocktail had no dramatic effect on RII␤ subunit recovery, although recoveries seemed slightly lower than greater in the presence of this protease inhibitor (Fig. 6D) . Even though the immunoblots were intentionally overexposed, there was little evidence of altered proteolytic processing of the RII␤ subunit of PKA in tissues prepared from transgenic compared with wild-type mice. Tissues excised from a set of older Q227L G␣ s transgenic mice (18 mo old) displayed the same expression pattern as observed in the 4-mo-old mice. The quantitative aspects of the immunoblotting of PKA subunits was tested and shown to be essentially linear within the range of protein loading (5-20 g) used in these studies (Fig.  6E) . The increased expression of PKA regulatory subunits, but a normal level of catalytic subunit, provides a likely explanation for the reduction in PKA activity in fat and suggests that chronic elevation of G␣ s activity and/or of intracellular cAMP may provoke several adaptive responses that act to dampen the cAMP signaling pathway.
DISCUSSION
To achieve the creation of a chimeric mouse model, we employed a transgene in which the expression of Q227L G␣ s was regulated by the promoter for the PEPCK gene. The PEPCK promoter offers a number of advantages for this line of investigation (12) . The PEPCK promoter is silent in utero, which ensured that the transgene would be carried by a viable pup. Although this design precludes expression until after birth, it seemed a valuable compromise. Germline alterations in the expression of G␣ s (i.e., Ϫ / Ϫ knockouts) to date have not yield viable pups (26) . Secondly, the PEPCK promoter is not leaky, is relatively strong, and maintains a level of expression sustained throughout adulthood. We demonstrated that the expression of Q227L G␣ s was inducible in vitro in rat hepatoma cells and that the transgene was expressed in vivo in targeted organs. The tissue-selective expression of the PEPCK promoter was most desirable, i.e., we achieved the creation of a "chimeric" mouse in which Q227L G␣ s expression was confined to adipose tissue, liver, and skeletal muscle. As deduced from immunoblotting experiments, the expression of Q227L G␣ s achieved ϳ40% of that observed for the endogenous G␣ s .
Phenotypically, the Q227L G␣ s transgenic mice were quite normal on a gross level. The transgenic mice were fertile, they procreated, and they displayed gross body mass, organ weights, and growth curves that were indistinguishable from those of their nontransgenic littermates or mice of the same age and sex. Although expression of Q227L G␣ s was observed in liver, a tissue targeted by the PEPCK gene promoter, we observed no hepatomegaly. Hepatomegaly has been observed in some patients with MAS, who show expression of the constitutively active G␣ s in liver among other targeted tissues (18) . We did observe, however, a delayed rectification of blood glucose after the administration of a paired t-test) . B: immunoblotting of PKA subunits was performed with whole homogenates of fat tissues (postnuclear supernatant after 2,000 g; 10-100 g protein) subjected to SDS-PAGE. The separated proteins were transferred to nitrocellulose membranes, and the blots were stained with mouse monoclonal antibodies for PKA catalytic (cat) and regulatory (R) subunits. The immune complexes were visualized with ECL methods and quantified with imaging densitometer. *P Ͻ 0.05 (paired t-test) for the difference between WT and Q227L mouse preparations (n ϭ 4). C: analysis of the subcellular distribution of PKA catalytic and regulatory subunits in total homogenate (2,000 g, 5 min) postnuclear supernatants and the resultant nuclear fraction prepared from whole homogenates of fat tissues obtained from WT and Q227L mice. Samples were subjected to SDS-PAGE, immunoblotting, and staining with subunit-specific antibodies. Equivalent amounts of homogenate were subjected to no further processing (H) or centrifugation, yielding the postnuclear supernatant (S) and nuclear (N) fractions. The results presented are from a single experiment. D: analysis of RII␤ subunit of PKA performed in the standard cocktail of protease inhibitors in the absence and presence of 0.2 mM benzamidine. Tissue was excised from the standard 4-mo-old control wild-type mice (WT4) or their transgenic counterparts (TG4). Tissue sampling was also obtained from 18-mo-old mice (TG18). Samples were otherwise prepared as in B. The immunoblots were intentionally overexposed to reveal any marked proteolytic degradation products that might differentiate WT from TG mice. Results shown are from a single representative experiment. E: quantitative immunoblotting of RII␤ subunit of PKA. Samples were prepared as in B. Sampling loading was varied from 0.1 to 40 g protein/lane. Immunoblots were subjected to image densitometry and quantified. All assays were performed with samples at loading concentration within the linear region of the plot. The results displayed are from a single experiment.
bolus of glucose. The delay was pronounced and required an additional 2-3 h for the transgenic mice to rectify glucose levels to those of their littermates. Both G␣ s (25, 26) and G␣ i2 (13) have been shown to influence insulin action and glucose metabolism in vivo. Loss-offunction mutants lacking G␣ i2 display frank insulin resistance (13) , whereas gain-of-function mutants of G␣ i2 , such as the Q205L G␣ i2 , yield an insulinomimetic state (1). The G␣ s Ϫ / Ϫ knockouts have proven lethal in mice, whereas the heterozygotes demonstrate increased insulin sensitivity (25) . In the current studies the gain-of-function Q227L G␣ s mice display the opposite phenotype of the loss-of-function G␣ s Ϫ / ϩ heterozygotes, showing impaired glucose tolerance.
The modest increase in intracellular cAMP levels that accompanied expression of the gain-of-function, constitutively active Q227L G␣ s in vivo was unexpected. However, earlier studies provide some precedent for these paradoxical observations. Overexpression of wild-type G␣ s targeted to heart created mice with enhanced chronotropic and ionotropic responses to sympathetic stimulation, cardiomyopathy with age, and increased apoptosis (2, 3) . Although expression of wild-type G␣ s in the heart was increased 2.8-fold, basal levels of adenylyl cyclase activity were unaffected (2). These observations support the premise that addition to the possible molar excess of G␣ s may have limited consequences for cAMP levels (16) . The studies reported herein, however, involved targeted overexpression of a constitutively active mutant of G␣ s , not the wild-type form. The expression of a constitutively active form of G␣ s in adipocytes did result in elevated basal cAMP levels, but the increase was modest, apparently reflecting some adaptive response(s) provoked by the elevation of intracellular cAMP. The increases in G␣ i2 expression and cAMP-specific PDE observed in the Q227L G␣ s mice may partially explain the adaptive response observed in the adipocytes. These adaptive responses may not be universal. In rat vascular smooth muscle cells in culture treated with an adenovirusdirected vector harboring Q227L G␣ s , resting cAMP levels were found to increase 10-fold, although the expression of Q227L G␣ s was clearly more robust than that obtained with the PEPCK gene promoter used here (8) . Our laboratory showed earlier (5) that increasing intracellular cAMP levels in various cells in culture provoked an increase in G␣ i2 mRNA and a threefold increase in G␣ i2 . Here, we demonstrate a likely correlate in vivo that chronic increases in cAMP levels may increase G␣ i2 expression in both fat and liver. We examined a second G␣ s readout, activation of pp60Src nonreceptor tyrosine kinase (11), but found no Q227L G␣ s -induced change in the amount of Src or its phosphorylation (data not shown). Thus the cellular context and adaptive changes in PDE and in G␣ i2 may be important in defining the extent to which expression of Q227L G␣ s translates into comparable increases in resting cAMP, a primary readout for G␣ s .
The most exciting adaptive response observed involves the expression of PKA subunits. Studies in human neoplastic B-(Reh) cells in culture have reported increased expression of both the catalytic subunit and the RI regulatory subunit mRNA in response to elevated cAMP levels, although immunoreactive RI␣ and C␣ levels were observed to decline in response to an eightfold elevation of cAMP by forskolin stimulation (22) . In Sertoli MSC-1 cells in culture, elevation of cAMP levels leads to an increase in the expression of RII␤ only, not RI␣, RII␣, C␣, or C␤ (7, 9) . Here we made use of targeted expression of Q227L G␣ s in mice to address this issue in vivo. In adipocytes from Q227L G␣ s mice, expression of the catalytic subunit of PKA was unaffected. Expressions of RI␣, RII␣, and RII␤, in contrast, were all increased in both fat and liver from Q227L G␣ s mice. This increased abundance of the regulatory subunits of PKA occurred with no apparent change in the amount of PKA cat, moderating PKA activity and constituting an important part of a possible adaptive response to increased cAMP levels. Taking into consideration the modest changes in cAMP that were noted in response to the expression of the Q227L G␣ s in vivo, we only can speculate that such adaptive changes, although related to expression of the transgene, are directly related to the change in intracellular cAMP. Indeed, if elevated cAMP levels were driving some of these adaptive changes, the adaptive changes may have already succeeded in attenuating elevated cAMP levels in this interesting mouse model. Levels of expression of PKA regulatory and catalytic subunits as well as PDE have not been analyzed in tissue samples from patients with MAS, but they may well provide a basis for some adaptive correction to the presence of a constitutively active G␣ s .
